SCHEMBL19973503

SCHEMBL19973503

Cn1nccc1CN[C@H]1CCOc2c(C(=O)Nc3ccc(F)c(F)c3)cccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 3/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAOB P27338 2/20 0.36
TRPV1 Q8NER1 2/20 0.36
HTR2A P28223 1/20 0.36
TP53 P04637 2/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
PKM P14618 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
AURKA O14965 1/20 0.35
AURKB Q96GD4 1/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
POLB P06746 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
AXL P30530 1/20 0.35
CRACR2A Q9BSW2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19973505 1.00 PTGES (0.39) PTGESMEN1KMT2AMAOBTRPV1
SCHEMBL21189251 0.86 TRPV1 (0.37) PTGESMEN1KMT2AMAOBTRPV1
SCHEMBL23309970 0.82 AURKA (0.39) PTGESMAOBTRPV1TP53NPC1
SCHEMBL19973439 0.79 TP53 (0.41) PTGESMEN1KMT2AMAOBTRPV1
SCHEMBL19973440 0.79 TP53 (0.41) PTGESMEN1KMT2AMAOBTRPV1
SCHEMBL19973487 0.79 TP53 (0.41) PTGESMEN1KMT2AMAOBTP53
SCHEMBL19973488 0.79 TP53 (0.41) PTGESMEN1KMT2AMAOBTP53
SCHEMBL19973586 0.78 TP53 (0.46) PTGESMEN1KMT2AMAOBTRPV1
SCHEMBL19973433 0.78 TP53 (0.46) PTGESMEN1KMT2AMAOBTRPV1
SCHEMBL19973432 0.78 TP53 (0.46) PTGESMEN1KMT2AMAOBTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US claimed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US claimed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO claimed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed
WO-2018052967-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS PTGES 4518/4885MEN1 1933/4885KMT2A 155/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS PTGES 4518/4885MEN1 1933/4885KMT2A 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.